Targeting fusions for improved outcomes in oncology treatment.

07:00 EST 3rd December 2019 | BioPortfolio

Summary of "Targeting fusions for improved outcomes in oncology treatment."

Fusions are increasingly pursued as oncology therapeutic targets. The current study evaluated differences in outcomes for fusion versus nonfusion targets.


Journal Details

This article was published in the following journal.

Name: Cancer
ISSN: 1097-0142


DeepDyve research library

PubMed Articles [26987 Associated PubMed Articles listed on BioPortfolio]

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.

NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, ...

Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.

The use of next-generation sequencing for fusion identification is being increasingly applied and aids our understanding of tumor biology. Some fusions are responsive to approved targeted agents, whil...

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.

Although rare, NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC). We report the response of a metastatic CTRC-NTRK1 gene fusion-positive PDAC to targeted t...

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.

The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery...

Radiation Oncology Quality Assessment Tool: A proposal for a new audit tool in modern radiation oncology.

As a consequence of the development of improved treatment techniques and utilisation of digital records in radiation oncology, the RANZCR Peer Review Audit Tool has become outdated. The aim of this in...

Clinical Trials [4780 Associated Clinical Trials listed on BioPortfolio]

Targeting Methods of Botulinum Toxin Injections for Cervical Dystonia

Botulinum toxin injections are the treatment of choice for cervical dystonia. Even if this treatment is successful for most of the patients, partials or completes failures still remained. ...

Next-Generation Pre-Operative Targeting for Thalamic DBS in the Treatment of Tremor

Researchers are investigating improved methods of targeting deep brain stimulators for treatment of essential tremor relying on brain connectivity measures derived from MRI.

Palliative and Oncology Care Intervention: Symptom COACH

The investigators propose to conduct the first pilot trial of a collaborative palliative and oncology care intervention for HNC patients receiving CRT to assess the feasibility and accepta...

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to...

Osteopathic Manipulative Treatment in Oncology Patients' Management

The aim of present study was to study the osteopathic manipulative effects on pain relief and quality of life improvement on hospitalized oncology geriatric patients. A non-randomized comp...

Medical and Biotech [MESH] Definitions

Physicians specializing in MEDICAL ONCOLOGY or its sub-specialties of RADIATION ONCOLOGY or SURGICAL ONCOLOGY.

The absence of a useful purpose or useful result in a diagnostic procedure or therapeutic intervention. The situation of a patient whose condition will not be improved by treatment or instances in which treatment preserves permanent unconsciousness or cannot end dependence on intensive medical care. (From Ann Intern Med 1990 Jun 15;112(12):949)

A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.

These evidence-based therapies to reduce symptoms associated with treatment of cancer.

A cytoplasmic receptor and peroxin that contains a series of TETRACOTIPEPTIDE REPEATS and binds to PEROXISOME TARGETING SIGNAL 1 (SKL-type). It is essential for protein import into PEROXISOMES; mutations in the PEX5 gene are associated with PEROXISOMAL DISORDERS such as ZELLWEGER SYNDROME.

Quick Search

DeepDyve research library

Relevant Topic

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Searches Linking to this Article